Cardiovascular and metabolic diseases are the leading causes of illness and death in British Columbia, yet patients with similar clinical profiles often experience very different outcomes. Genomic testing holds promise for earlier detection and more targeted management, but clinical implementation remains limited by uneven access to testing and the lack of integration between genetic results and health‑system data. This gap makes it difficult to demonstrate where genomics can meaningfully improve care at scale.

The VECTOR project aims to address this gap by evaluating how genetic information can strengthen prediction and management of cardiometabolic disease in British Columbia. Led by Dr. Teresa Tsang at the University of British Columbia, the project leverages data from the province‑wide MOSAIC study, which is enrolling 8,000 participants undergoing routine heart imaging across multiple health authorities. VECTOR focuses on variants in genes linked to heart disease, metabolic conditions and medication response, and assesses their relevance in a real clinical setting.

Using whole genome sequencing, echocardiography measurements and blood‑based markers, the project will securely link genetic findings with longitudinal clinical and administrative data through Health Data Platform BC. Genetic variants will be grouped by clinical actionability using established guidelines and analyzed alongside outcomes such as disease progression, hospital admissions and medication response.

By generating BC‑specific evidence, VECTOR aims to clarify where genomics can add value for patients and the healthcare system. The project has the potential to support earlier diagnosis, more targeted treatment and more efficient use of health resources, while laying a scalable foundation for integrating genomics into future care pathways in British Columbia.